Arno C. Andeweg

Dr. Arno C. Andeweg


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
ABAlessandra Buoninfante
Alessandra Buoninfante
AAArno C. Andeweg
Arno C. Andeweg
GGGeorgy Genov
Georgy Genov
MCMarco Cavaleri
Marco Cavaleri
Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.

9 November 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
ABAlessandra Buoninfante
Alessandra Buoninfante
AAArno C. Andeweg
Arno C. Andeweg
Alexander BakerAlexander Baker
Alexander Baker
MBMitesh Borad
Mitesh Borad
NCNigel Crawford
Nigel Crawford
MCMarco Cavaleri
Marco Cavaleri
Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been demonstrated in clinical trials and next by their real world use through the course of the ongoing COVID-19 pandemic. However, very rare adverse events have been detected post-authorization in certain parts of the world. This meeting report summarizes an EMA workshop’s discussion on the epidemiology, clinical presentation and biology of thrombosis with thrombocytopenia syndrome after adenovirus vector COVID-19 vaccination. General agreement was reached by international regulators, scientists and developers on the steps needed to fill the gaps in the characterization of this new syndrome. In particular, actions should be taken to improve the post-vaccination surveillance activities in low and middle income countries and investigate potential genetic predisposition factors.

11 November 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VJVictor L. Jong
Victor L. Jong
IAInge M. L. Ahout
Inge M. L. Ahout
HHHenk-Jan van Den Ham
Henk-Jan van Den Ham
JJJop Jans
Jop Jans
FZFatiha Zaaraoui-Boutahar
Fatiha Zaaraoui-Boutahar
AAArno C. Andeweg
Arno C. Andeweg
Respiratory syncytial virus (RSV) causes infections that range from common cold to severe lower respiratory tract infection requiring high-level medical care. Prediction of the course of disease in individual patients remains challenging at the first visit to the pediatric wards and RSV infections may rapidly progress to severe disease. In this study we investigate whether there exists a genomic signature that can accurately predict the course of RSV. We used early blood microarray transcriptome profiles from 39 hospitalized infants that were followed until recovery and of which the level of disease severity was determined retrospectively. Applying support vector machine learning on age by sex standardized transcriptomic data, an 84 gene signature was identified that discriminated hospitalized infants with eventually less severe RSV infection from infants that suffered from most severe RSV disease. This signature yielded an area under the receiver operating characteristic curve (AUC) of 0.966 using leave-one-out cross-validation on the experimental data and an AUC of 0.858 on an independent validation cohort consisting of 53 infants. A combination of the gene signature with age and sex yielded an AUC of 0.971. Thus, the presented signature may serve as the basis to develop a prognostic test to support clinical management of RSV patients.

13 March 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CWCornelia A M van de Weg
Cornelia A M van de Weg
HHHenk-Jan van Den Ham
Henk-Jan van Den Ham
MBMaarten A Bijl
Maarten A Bijl
FAFatih Anfasa
Fatih Anfasa
FZFatiha Zaaraoui-Boutahar
Fatiha Zaaraoui-Boutahar
AAArno C. Andeweg
Arno C. Andeweg
Dengue virus (DENV) infection causes viral haemorrhagic fever that is characterized by extensive activation of the immune system. The aim of this study is to investigate the kinetics of the transcriptome signature changes during the course of disease and the association of genes in these signatures with clinical parameters. Sequential whole blood samples from DENV infected patients in Jakarta were profiled using affymetrix microarrays, which were analysed using principal component analysis, limma, gene set analysis, and weighted gene co-expression network analysis. We show that time since onset of disease, but not diagnosis, has a large impact on the blood transcriptome of patients with non-severe dengue. Clinical diagnosis (according to the WHO classification) does not associate with differential gene expression. Network analysis however, indicated that the clinical markers platelet count, fibrinogen, albumin, IV fluid distributed per day and liver enzymes SGOT and SGPT strongly correlate with gene modules that are enriched for genes involved in the immune response. Overall, we see a shift in the transcriptome from immunity and inflammation to repair and recovery during the course of a DENV infection. Time since onset of disease associates with the shift in transcriptome signatures from immunity and inflammation to cell cycle and repair mechanisms in patients with non-severe dengue. The strong association of time with blood transcriptome changes hampers both the discovery as well as the potential application of biomarkers in dengue. However, we identified gene expression modules that associate with key clinical parameters of dengue that reflect the systemic activity of disease during the course of infection. The expression level of these gene modules may support earlier detection of disease progression as well as clinical management of dengue. An acute dengue virus infection usually starts with a febrile disease phase that can progress to severe disease around the time fever abates (defervescence). Here we study dengue patients that were included very early after the onset of disease and carefully monitored in a longitudinal cohort study. Our results show that time after the onset of disease has a major impact on the transcriptome profile of patients with dengue, which is confirmed by comparing our results with three other dengue studies that included patients at different disease stages. There is a gradual shift in transcriptome profile from an ‘immunity & inflammation’- to a ‘repair & recovery’ phenotype. Furthermore, the expression of gene network modules could be linked to specific clinical parameters of dengue virus infection. Platelet counts and the levels of fibrinogen and albumin are shown to be good markers for the activity and timing of the disease, reflecting relevant biological processes in the patient. In contrast, conventional WHO classification systems did not show any association with any of the 25 gene modules identified and only yielded a few differentially expressed genes. The expression level of gene modules specific for certain biological processes in dengue support earlier detection of progression to severe disease and may improve clinical management.

6 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MGMiranda De Graaf
Miranda De Graaf
SHSander Herfst
Sander Herfst
JAJamil Aarbiou
Jamil Aarbiou
PBPeter C Burgers
Peter C Burgers
FZFatiha Zaaraoui-Boutahar
Fatiha Zaaraoui-Boutahar
AAArno C. Andeweg
Arno C. Andeweg
Human metapneumovirus (HMPV) encodes a small hydrophobic (SH) protein of unknown function. HMPV from which the SH open reading frame was deleted (HMPVΔSH) was viable and displayed similar replication kinetics, cytopathic effect and plaque size compared with wild type HMPV in several cell-lines. In addition, no differences were observed in infection efficiency or cell-to-cell spreading in human primary bronchial epithelial cells (HPBEC) cultured at an air-liquid interphase. Host gene expression was analyzed in A549 cells infected with HMPV or HMPVΔSH using microarrays and mass spectrometry (MS) based techniques at multiple time points post infection. Only minor differences were observed in mRNA or protein expression levels. A possible function of HMPV SH as apoptosis blocker, as proposed for several members of the family Paramyxoviridae, was rejected based on this analysis. So far, a clear phenotype of HMPV SH deletion mutants in vitro at the virus and host levels is absent.

3 December 2019 in Immunogenetics
Verified
Journal Article
Open access
PDF file
BGBram Gerritsen
Bram Gerritsen
APAridaman Pandit
Aridaman Pandit
FZFatiha Zaaraoui-Boutahar
Fatiha Zaaraoui-Boutahar
MHMirjam van den Hout
Mirjam van den Hout
WIWilfred van IJcken
Wilfred van IJcken
AAArno C. Andeweg
Arno C. Andeweg
The domestic ferret, Mustela putorius furo, is an important mammalian animal model to study human respiratory infection. However, insufficient genomic annotation hampers detailed studies of ferret T cell responses. In this study, we analyzed the published T cell receptor beta (TRB) locus and performed high-throughput sequencing (HTS) of peripheral blood of four healthy adult ferrets to identify expressed V, D, J, and C genes. The HTS data is used as a guide to manually curate the expressed V, D, J, and C genes. The ferret locus appears to be most similar to that of the dog. Like other mammalian TRB loci, the ferret TRB locus contains a library of variable genes located upstream of two D-J-C gene clusters, followed by a (in the ferret non-functional) V gene with an inverted transcriptional orientation. All TRB genes (expressed or not) reported here have been approved by the IMGT/WHO-IUIS nomenclature committee.